Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Gene Test Detects Early Mouth Cancer

By LabMedica International staff writers
Posted on 24 Oct 2012
A gene test that can detect precancerous cells in patients with benign-looking mouth lesions could potentially allow at-risk patients to receive earlier treatment, significantly improving their chance of survival. More...


The test is less invasive than the standard histopathology methods as it requires only a 1-2 mm piece of tissue and it takes less than three hours to get the results, compared to up to a week for standard histopathology where biopsy tissue taken during an operation is examined under a microscope by a pathologist.

Scientists at Queen Mary, University of London (UK) showed that the quantitative Malignancy Index Diagnostic System (qMIDS) test had a cancer detection rate of 91% to 94% when used on more than 350 head and neck tissue specimens from 299 patients in the UK and Norway. The qMIDS test measures the levels of 16 genes, which are converted, via a diagnostic algorithm, into a "malignancy index" which quantifies the risk of the lesion becoming cancerous.

The test is based on a cancer gene encoding the Forkhead box protein (FOXM1) - (isoform B). The FOXM1 gene is highly expressed in many cancer types. The 14 associated genes are implicated in the regulation of the cell cycle, differentiation, aging, genomic stability, epigenetic and stem cell renewal. Two reference genes are included in the test.

Diagnostic test performance was assessed using detection rate (DR) and false-positive rate (FPR).The median qMIDS scores were 1.3, in healthy tissue, 2.9 in dysplasia, and 6.7 in head and neck squamous cell carcinomas (HNSCC).. At a qMIDS cut-off of 4.0, DR was 94% and FPR was 3.2% for a Norwegian dataset; and DR was 91% and FPR was 1.3% for the UK dataset. In this study, the investigators further demonstrated the transferability of qMIDS for diagnosing 58 premalignant human vulva and 21 skin squamous cell carcinomas, illustrating its potential clinical use for other cancer types.

Mouth cancer affects more than 6,200 people in the UK each year and more than half a million people worldwide, with global figures estimated to rise above one million a year by 2030. Muy-Teck Teh, PhD, the lead investigator and inventor of the test, said, “A sensitive test capable of quantifying a patient's cancer risk is needed to avoid the adoption of a 'wait-and-see' intervention. Detecting cancer early, coupled with appropriate treatment can significantly improve patient outcomes, reduce mortality and alleviate long-term public healthcare costs.” The study was published on October 4, 2012, in the journal International Journal of Cancer.

Related Links:

Queen Mary, University of London



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.